New drug evaluations. Triazolam

Drug Intelligence & Clinical Pharmacy
P D Kroboth, R P Juhl

Abstract

Triazolam is a sedative/hypnotic triazolobenzodiazepine, structurally related to alprazolam. Recently, it has been approved for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Triazolam is metabolized with a half-life of 1.5-5.0 hours. Its one active metabolite, which appears in low concentrations and is inactivated rapidly, is not thought to contribute to its pharmacologic activity. Triazolam has been shown to decrease sleep latency and the number of nocturnal awakenings while increasing total sleep time in patients with insomnia. Sleep electroencephalogram studies show that triazolam has no effect on delta-sleep (Stages 3 and 4) and has variable effects on rapid-eye-movement sleep. Nighttime administration of triazolam increases daytime alertness in insomniacs and improves or has no effect on performance. The reported side effects are similar to those of other benzodiazepines and include drowsiness, dizziness, and dry mouth. The recommended dosage of triazolam is 0.25-0.5 mg hs. A reduced initial dose of 0.125 mg should be used in geriatric patients.

References

Jan 1, 1976·The Journal of International Medical Research·L F FabreR T Harris
May 1, 1978·Journal of Clinical Pharmacology·M Leibowitz, A Sunshine
Jan 1, 1978·The Journal of International Medical Research·A J Bowen
Jan 1, 1978·The Journal of International Medical Research·K K Okawa, G S Allens
Sep 8, 1979·Lancet·C van der Kroef
Sep 22, 1979·Lancet·N MacLeod, C H Kratochvil
Jan 1, 1975·Psychopharmacologia·G VogelK Sexton
May 1, 1975·Clinical Pharmacology and Therapeutics·A Sunshine
Apr 1, 1977·Journal of Clinical Pharmacology·A KalesM B Scharf
Feb 1, 1974·Journal of Clinical Pharmacology·W VeldkampH V Demissianos
Feb 1, 1980·British Journal of Clinical Pharmacology·A N Nicholson, B M Stone
Apr 12, 1980·Lancet·L Lasagna
Apr 25, 1980·Science·K M HartseF Zorick
Jan 1, 1980·The Journal of International Medical Research·V PegramP Linton
Jan 1, 1980·Psychopharmacology·C OguraW M Wardell
Jan 1, 1980·The Journal of International Medical Research·P M PiccioneT Roth
Jan 1, 1981·Clinical Pharmacology and Therapeutics·F S EbertsR W Vliek
Apr 1, 1982·Drug Intelligence & Clinical Pharmacy·T R Einarson, E S Yoder
Feb 1, 1982·The Journal of Pharmacy and Pharmacology·V H Sethy, D W Harris
Jan 1, 1982·Psychopharmacology·C L Spinweber, L C Johnson
Jan 1, 1982·Sleep·W C DementM A Carskadon
Jan 1, 1981·British Journal of Clinical Pharmacology·R C Hall, S Zisook
Mar 1, 1983·British Journal of Clinical Pharmacology·D J GreenblattR I Shader
Mar 1, 1980·British Journal of Clinical Pharmacology·A N Nicholson

Citations

Jan 1, 1990·Journal of Psychoactive Drugs·V L Martin
Mar 1, 1992·The Annals of Pharmacotherapy·J F Martí-MassóG López de Dicastillo
Jan 1, 1987·Psychopharmacology·A M Nikaido, E H Ellinwood

Related Concepts

Metazoa
Financial Cost
Drug Interactions
Electroencephalogram
Anti-Anxiety Effect
Trilam

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Torsion Dystonia

Torsion dystonia is a movement disorder characterized by loss of control of voluntary movements appearing as sustained muscle contractions and/or abnormal postures. Here is the latest research.

Generating Insulin-Secreting Cells

Reprogramming cells or using induced pluripotent stem cells to generate insulin-secreting cells has significant therapeutic implications for diabetics. Here is the latest research on generation of insulin-secreting cells.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Epigenome Editing

Epigenome editing is the directed modification of epigenetic marks on chromatin at specified loci. This tool has many applications in research as well as in the clinic. Find the latest research on epigenome editing here.